Additionally, small studies suggest medications like sodium-glucose cotransporter-2 inhibitors (e.g., dapagliflozin) may reduce EFT and improve LV systolic function in patients with type 2 diabetes [31]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.